Compare DELL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DELL | SNY |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.7B | 116.8B |
| IPO Year | 2013 | N/A |
| Metric | DELL | SNY |
|---|---|---|
| Price | $149.82 | $43.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $165.86 | $61.50 |
| AVG Volume (30 Days) | ★ 7.8M | 4.1M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | 1.43% | ★ 3.64% |
| EPS Growth | N/A | N/A |
| EPS | ★ 5.34 | N/A |
| Revenue | ★ $95,567,000,000.00 | N/A |
| Revenue This Year | $21.52 | $3.01 |
| Revenue Next Year | $10.92 | $5.80 |
| P/E Ratio | $27.58 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $66.25 | $43.51 |
| 52 Week High | $168.08 | $59.17 |
| Indicator | DELL | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 66.73 | 32.23 |
| Support Level | $145.09 | N/A |
| Resistance Level | $152.70 | $48.97 |
| Average True Range (ATR) | 6.15 | 0.68 |
| MACD | 1.38 | -0.36 |
| Stochastic Oscillator | 90.87 | 6.20 |
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three market shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners, and also relies heavily on channel partners to fulfill its sales.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.